Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$86.97 USD

86.97
705,520

+8.81 (11.27%)

Updated Nov 7, 2024 12:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks News

Haemonetics Plasma Arm Grows Strong, Blood Center Sluggish

Haemonetics (HAE) registers strong top-line growth, banking on Plasma, TEG, hemostasis management as well as a strong cash position. Blood Center drag continues.

    Cardiovascular Systems Unveils Favorable LIBERTY 360 Data

    LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.

      Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company

      Zacks.com featured highlights: The Chemours Company, Haemonetics Corporation and The Brink's Company

        3 Best Stocks with Upgraded Broker Ratings to Invest In Now

        Selecting stocks from the vast investment universe is not an easy task. In such a situation, sound broker advice helps to pick the right stocks.

          Haemonetics Banks on Solid Plasma & Haemonetics Management

          Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

            Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

            Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.

              Why Earnings Season Could Be Great for Haemonetics (HAE)

              Haemonetics (HAE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

                Can PerkinElmer (PKI) Spring a Surprise in Q2 Earnings?

                Despite an upbeat outlook, volatility in the foreign exchange rate is likely to mar PerkinElmer's (PKI) results in the second quarter.

                  Haemonetics Plasma Arm Advances, Blood Center Sluggish

                  On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).

                    Haemonetics Rides on Solid Plasma, Slows Blood Center Growth

                    On Jun 13, we issued an updated research report on Haemonetics Corporation (HAE).

                      Haemonetics (HAE) Down 2.2% Since Earnings Report: Can It Rebound?

                      Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Haemonetics (HAE) Tops Q4 Earnings, Sales, Issues 2018 View

                        Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 39 cents in the fourth quarter of fiscal 2017, up 5.4% year over year.

                          Haemonetics' Plasma Group Strong, Blood Center Group a Drag

                          On Apr 11, we issued an updated research report on Braintree, MA-based Haemonetics Corporation (HAE), a leading provider of blood management solutions.

                            Why Is Haemonetics (HAE) Up 3.5% Since the Last Earnings Report?

                            Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates

                              Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.

                                Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More

                                Let's take a look at the major Medical products stocks slated to release their quarterly reports on Feb 6.

                                  Walgreens Boots (WBA) Beats Q1 Earnings, Trims EPS View

                                  Walgreens Boots Alliance, Inc. (WBA) reported adjusted earnings per share (EPS) of $1.10 in first-quarter fiscal 2017, up 6.8% from the year-ago quarter.

                                    Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite

                                    Bruker Corporation (BRKR) recently announced the buyout of Hennigsdorf, Germany-based InVivo Biotech Services GmbH.

                                      Bruker Buys SCiLS, Expands in Mass Spectrometry Imaging

                                      Bruker Corporation (BRKR) recently announced the acquisition of Bremen, Germany-based software solutions developer, SCiLS GmbH.

                                        ResMed Achieves Key Milestone in Sleep-Disordered Breathing

                                        After one billion nights of sleep data was downloaded using ResMed's remote patient monitoring platform AirView, the company reached a landmark in the field of sleep research and treatment of sleep apnea.

                                          Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay

                                          Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.

                                            Illumina Fettered With Losses: Can It Bounce Back in 2017?

                                            During majority of the past one year, Illumina (ILMN) lagged the Zacks classified broader Medical - Biomedical and Genetics industry.

                                              Masimo to Launch Advanced Monitoring Technologies in India

                                              Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.

                                                OPKO Health (OPK) Reports Failure in hGH-CTP Phase 3

                                                OPKO Health Inc. (OPK) announced failure in its data analysis of the Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults.

                                                  Abaxis (ABAX) Veterinary Prospects Bright: Should You Hold?

                                                  On Jan 2, 2017, Abaxis Inc. (ABAX), a leading manufacturer of portable medical and veterinary blood analysis systems, was upgraded to a Zacks Rank #3 (Hold).